Medical Developments International (ASX:MVP) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International Debt-to-Equity?

Medical Developments International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.37 Mil. Medical Developments International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$2.06 Mil. Medical Developments International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$75.69 Mil. Medical Developments International's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medical Developments International's Debt-to-Equity or its related term are showing as below:

ASX:MVP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 0.44
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Medical Developments International was 0.44. The lowest was 0.00. And the median was 0.05.

ASX:MVP's Debt-to-Equity is ranked better than
88.79% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs ASX:MVP: 0.03

Medical Developments International Debt-to-Equity Historical Data

The historical data trend for Medical Developments International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medical Developments International Debt-to-Equity Chart

Medical Developments International Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.05

0.03

Medical Developments International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.03	0.03	0.03

Competitive Comparison of Medical Developments International's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Developments International's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Debt-to-Equity falls into.

Medical Developments International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medical Developments International's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.352	+	2.208)	/	81.315
	=	0.03

Medical Developments International's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.365	+	2.061)	/	75.693
	=	0.03

Medical Developments International (ASX:MVP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Medical Developments International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medical Developments International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medical Developments International (ASX:MVP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Caribbean Drive, Scoresby, VIC, AUS, 3179

Website

https://www.medicaldev.com

Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International (ASX:MVP) Headlines

No Headlines